Group 2

Yield10 Bioscience Reports that Proprietary Varieties of Winter Camelina Show Tolerance to Commonly Used Herbicides in First Field Tests

Retrieved on: 
Thursday, February 29, 2024
Weed control, Soil, Yield10 Bioscience, Plant, IMI, Lead, Group 2, Herbicide, USDA, Agriculture

Yield10 has previously reported herbicide tolerance in spring Camelina, where the Company has selected lead and back-up commercial-quality lines for development.

Key Points: 
  • Yield10 has previously reported herbicide tolerance in spring Camelina, where the Company has selected lead and back-up commercial-quality lines for development.
  • Preliminary interim results of these field tests indicated that Yield10’s stacked HT winter Camelina performed well on the field plots pre-treated with Group 2 herbicides.
  • The winter Camelina was planted, and the field plots were subsequently sprayed with glufosinate in accordance with the field trial design.
  • Winter Camelina engineered with glufosinate tolerance remained healthy, while field plots of Camelina without the herbicide tolerance trait did not survive the spray.

Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Pharmaceutical, AIDS, General Health, Health, Infectious Diseases, Hospitals, Clinical Trials, Bictegravir, ARV, CD4, Week, Doctor of Philosophy, Aes, Gilead Sciences, Fungal infection, Research, CROI, MDR, MD, Diarrhea, Science, Food, Female, Hook effect, ZAB, Conference, Constipation, European, Safety, Group 2, Black, Lancet, COVID-19, RNA, Public, Patient, Lenacapavir, Plasma, TAB, Observational study, HIV, Viral load

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of key data highlighting the breadth of its innovative HIV treatment research pipeline.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of key data highlighting the breadth of its innovative HIV treatment research pipeline.
  • “The latest findings across our HIV pipeline showcase the potential of multiple candidates to help transform HIV management,” said Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences.
  • It is estimated that up to 10% of people with HIV take a complex treatment regimen, defined as 2 or more pills each day.
  • Results showed that all three treatment groups had robust virologic suppression at six months, with consistently low viral loads throughout the study.

Rebamipide May Combat Low-Grade Inflammation in Post-COVID-19 Syndrome Patients

Retrieved on: 
Monday, February 19, 2024
Group 1, Coronavirus, AAAAI, Research, SARS-CoV-2, Doctor of Philosophy, Multimedia, Inflammation, Nonsteroidal anti-inflammatory drug, Enterocyte, Asthma, ELISA, Radical, Arthralgia, Group 2, COVID-19, CRP, COVID, Patient, Journal, Rehabilitation, Plasma, Ageing, Rebamipide, American Academy, Pharmaceutical industry

MILWAUKEE, Feb. 19, 2024 /PRNewswire-PRWeb/ -- Rebamipide may be useful for rehabilitation of patients with SARS-CoV-2 post-COVID syndrome according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Washington, DC, this month.

Key Points: 
  • "This study revealed higher levels of lipopolysaccharide-binding protein, and lower levels of bacterial permeability protein in patients with post COVID syndrome.
  • Rebamipide, by reducing intestinal permeability, reduces endotoxin load, lowering the level of low-grade inflammation.
  • To explore Rebamipide's usefulness for rehabilitating SARS-CoV-2 post-COVID syndrome patients, researchers examined 62 patients, aged 42-55 years with post-COVID-19 syndrome using nonsteroidal anti-inflammatory drugs for joint pain.
  • Given the effects of SARS-CoV-2 on enterocytes, the results suggest that Rebamipide may be useful for rehabilitation of patients with SARS-CoV-2 post-COVID syndrome.

Notice convening the Annual General Meeting of AB Electrolux

Retrieved on: 
Friday, February 16, 2024
Transfer, Group 1, Person, International assignment, ABS, Sale, Electrolux, Annual report, ATTN:, Election, Legislation, Housing, Nomination, Annual general meeting, Committee, The Annual Report, Social Security, AMF, Companies Act, Malus, Group 2, PwC, Remuneration, LTI, Motivation, Mass meeting, Group 4, Retirement, General counsel, CO2, Employment, Auditor, Editorial, Chapter Eight, Group 5, Corporate governance, Group 3, Group 7, Swedish Bar Association, Audit committee, Investor AB, Administration, Disability, Report, Annual, STI, Management

The Board of Directors proposes that the following guidelines for remuneration shall be approved by the Annual General Meeting of the Company.

Key Points: 
  • The Board of Directors proposes that the following guidelines for remuneration shall be approved by the Annual General Meeting of the Company.
  • The principles shall be applied to employment and consultancy agreements entered into after the 2024 Annual General Meeting, and to changes made to existing agreements thereafter.
  • The proposal to the 2024 Annual General Meeting for resolution on guidelines for remuneration corresponds, in all material aspects, with the guidelines adopted by the 2020 Annual General Meeting.
  • The resolution of the Annual General Meeting to implement the Share Program 2024 according to a) above requires that more than half of the votes cast at the Annual General Meeting are in favor of the proposal.

Notice convening the Annual General Meeting of AB Electrolux

Retrieved on: 
Friday, February 16, 2024
Transfer, Group 1, Person, International assignment, ABS, Sale, Electrolux, Annual report, ATTN:, Election, Legislation, Housing, Nomination, Annual general meeting, Committee, The Annual Report, Social Security, AMF, Companies Act, Malus, Group 2, PwC, Remuneration, LTI, Motivation, Mass meeting, Group 4, Retirement, General counsel, CO2, Employment, Auditor, Editorial, Chapter Eight, Group 5, Corporate governance, Group 3, Group 7, Swedish Bar Association, Audit committee, Investor AB, Administration, Disability, Report, Annual, STI, Management

The Board of Directors proposes that the following guidelines for remuneration shall be approved by the Annual General Meeting of the Company.

Key Points: 
  • The Board of Directors proposes that the following guidelines for remuneration shall be approved by the Annual General Meeting of the Company.
  • The principles shall be applied to employment and consultancy agreements entered into after the 2024 Annual General Meeting, and to changes made to existing agreements thereafter.
  • The proposal to the 2024 Annual General Meeting for resolution on guidelines for remuneration corresponds, in all material aspects, with the guidelines adopted by the 2020 Annual General Meeting.
  • The resolution of the Annual General Meeting to implement the Share Program 2024 according to a) above requires that more than half of the votes cast at the Annual General Meeting are in favor of the proposal.

FDA Approves First Medication to Treat Severe Frostbite

Retrieved on: 
Wednesday, February 14, 2024
Human services, Group 1, Blood pressure, Division, Research, Aspirin, Headache, The, Frostbite, Cosmetics, Multimedia, Group 3, Flushing, Blood, Physician, FDA, Dietary supplement, Food, Dizziness, Skin, Nausea, Finger, Cardiology, Vomiting, Standard of care, Vaccine, Risk, Animal, Iloprost, Amputation, Safety, Heated tobacco product, Group 2, Nephrology, Public, Patient, Palpitations, Orthostatic hypertension, Hypotension, Priority review

SILVER SPRING, Md., Feb. 14, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation.

Key Points: 
  • SILVER SPRING, Md., Feb. 14, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation.
  • Frostbite can occur in several stages, ranging from mild frostbite that does not require medical intervention and does not cause permanent skin damage, to severe frostbite when both the skin and underlying tissue are frozen and blood flow is stopped, sometimes requiring amputation.
  • Iloprost's efficacy in treating severe frostbite was primarily established in an open-label, controlled trial that randomized 47 adults with severe frostbite, who all received aspirin by vein and standard of care, into one of three treatment groups.
  • The two other groups received other medications that are unapproved for frostbite, given with iloprost (Group 2) or without iloprost (Group 3).

Emergex Announces Authorisation from Philippines FDA to Initiate Phase I-II Clinical Trial of CoronaTcP™

Retrieved on: 
Wednesday, January 3, 2024
Entrepreneurship, CD8, FDA, Group 2, Disease, Trial of the century, Vaccination, Mutation, Water, Volunteering, SARS-CoV-2, Safety, Coronavirus, Group 1, Vaccine

Emergex received authorisation from the Philippines FDA to launch a Phase I-II clinical trial of CoronaTcP, its T cell-priming immune set-point candidate against Betacoronaviruses.

Key Points: 
  • Emergex received authorisation from the Philippines FDA to launch a Phase I-II clinical trial of CoronaTcP, its T cell-priming immune set-point candidate against Betacoronaviruses.
  • Emergex is progressing trial initiation plans, with an anticipated start date in Q2 2024.
  • The naNO-COVID 2 trial (NCT05633446) is a randomized, double-blind, placebo-controlled Phase I-II trial in the Philippines, which will investigate the safety and immunogenicity of CoronaTcP.
  • Professor Thomas Rademacher, Co-Founder and Chief Executive Officer, Emergex, commented: “We thank the Philippines FDA for rapidly approving this trial after a successful Phase I clinical trial in Switzerland.

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

Retrieved on: 
Thursday, December 14, 2023
Șaeș, Weight loss, Group 2, Therapy, Teriparatide, Pharmacokinetics, PD, Obesity, Osteoporosis, Biomarker, Ustekinumab, Human, Group 1, Safety, GIP, Pharmaceutical industry

SAN JOSE, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced pharmacodynamic data of an incretin triagonist of the GLP-1, GIP, and glucagon receptors delivered transenterically, which mimics the RaniPill route of administration. This follows Rani’s prior study demonstrating oral delivery of a GLP-1 receptor agonist with high bioavailability via the RaniPill capsule.

Key Points: 
  • - Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study –
    SAN JOSE, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced pharmacodynamic data of an incretin triagonist of the GLP-1, GIP, and glucagon receptors delivered transenterically, which mimics the RaniPill route of administration.
  • “The preclinical data announced today are highly encouraging, as the data highlights that transenteric delivery mimicking the RaniPill’s route of drug administration results in pharmacodynamics comparable to subcutaneous injection for an incretin triagonist,” said Talat Imran, Chief Executive Officer of Rani Therapeutics.
  • “In a previous preclinical study, Rani showed that the RaniPill capsule can orally deliver a GLP-1 receptor agonist with bioavailability and pharmacokinetics comparable to a subcutaneous injection.
  • In the recent study of an incretin triagonist, Rani obtained pharmacodynamic data showing weight loss and reduction in serum lipids comparable to that observed via the subcutaneous injection route.

USDA-APHIS Determines that Yield10 Bioscience’s Glufosinate Tolerant Camelina May Be Planted and Bred in the United States

Retrieved on: 
Wednesday, November 15, 2023
Yield10 Bioscience, Agriculture, EPA, Safety, Gene editing, USDA, BRS, Oil, CFR, Health, DHA, Group 2, Transport, Camelina

WOBURN, Mass., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that USDA-APHIS’s Biotechnology Regulatory Services (“BRS”) has determined that Yield10’s glufosinate tolerant Camelina sativa ("Camelina”) may be grown and bred in the United States. Yield10 submitted a Request for Regulatory Status Review (“RSR”) to the BRS under the SECURE Rule in June 2022 for glufosinate tolerant Camelina. The response from USDA-APHIS means that the agency does not consider the modified Camelina plant to be an increased plant pest risk as compared to unmodified Camelina and is therefore not subject to regulation under 7 CFR part 340 regulations. Yield10’s submission along with the USDA-APHIS BRS response is posted on the USDA’s website.

Key Points: 
  • Yield10 submitted a Request for Regulatory Status Review (“RSR”) to the BRS under the SECURE Rule in June 2022 for glufosinate tolerant Camelina.
  • “The regulatory clearance of glufosinate tolerant Camelina through USDA-APHIS represents a significant commercial milestone for Yield10,” said Kristi Snell, Ph.D., Chief Scientific Officer of Yield10 Bioscience.
  • We believe glufosinate tolerant Camelina will provide growers with new options for weed management allowing Camelina to fit seamlessly into crop rotations driving commercial adoption.
  • Yield10 is currently scaling-up seed inventory in anticipation of the commercial launch of glufosinate tolerant Camelina.

USDA-APHIS Determines that Yield10 Bioscience’s Stacked Herbicide Tolerant Camelina May Be Planted and Bred in the United States

Retrieved on: 
Wednesday, November 15, 2023
Yield10 Bioscience, Group 10 element, USDA, BRS, CFR, Sustainability, Consistency, Group 2, Soil, Agriculture, Management, Camelina, Ecology

In April 2023, Yield10 submitted Request for Confirmation of Regulatory Status packages to the BRS under the Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient (“SECURE”) Rule, for stacked HT Camelina varieties.

Key Points: 
  • In April 2023, Yield10 submitted Request for Confirmation of Regulatory Status packages to the BRS under the Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient (“SECURE”) Rule, for stacked HT Camelina varieties.
  • Yield10 is executing a program to develop and commercialize spring and winter Camelina varieties with stacked herbicide tolerance traits to achieve large-acreage adoption of the crop in North America.
  • “The regulatory clearance of our stacked HT Camelina represents another significant commercial milestone achieved by the Yield10 team, underscoring our commitment to establishing both technical and commercial leadership positions in Camelina,” said Kristi Snell, Ph.D., Chief Scientific Officer of Yield10 Bioscience.
  • “Earlier this year, we conducted our first field tests of stacked HT Camelina and reported positive results.